Treatment
Melphalan clinical trials
We’re tracking 64 recruiting studies that include Melphalan, each written for real people, not researchers, below.
Recruiting studies
- NCT06815003RecruitingPhase 2
Preventing Graft-Versus-Host Disease After Stem Cell Transplant
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
Duarte, CaliforniaAges 18–80 - NCT06875128RecruitingPhase 2
Liver-directed chemo with standard chemo for breast cancer
This trial tests if giving a high dose of chemotherapy directly into the liver, followed by standard chemotherapy, is safe and works better than standard chemo alone for people with breast cancer that has spread mostly to the liver.
Tampa, FloridaAges 18 years+ - NCT07052370RecruitingPhase 1
New stem cell transplant for children with high-risk blood cancer
This trial tests a special stem cell transplant from a half-matched family donor, designed to reduce rejection and infection risk. It may include a targeted drug (blinatumomab) to help kill remaining cancer cells.
Memphis, TennesseeAges Up to 21 years - NCT07199296RecruitingPhase 2
Study of orelabrutinib and rituximab with optional stem cell transplant for mantle cell lymphoma
This trial is testing a combination of two targeted drugs, orelabrutinib and rituximab, as a first treatment for mantle cell lymphoma (MCL). Some patients may also get a stem cell transplant. The goal is to see how well this approach works.
ShanghaiAges 14 years+ - NCT07228624RecruitingPhase 2
Ruxolitinib before, during, and after transplant for myelofibrosis
This trial tests whether taking the drug ruxolitinib before, during, and after a stem cell transplant helps older patients with myelofibrosis or certain related blood disorders. The goal is to see if this approach can improve transplant success and reduce side effects.
Seattle, WashingtonAges 18–75 - NCT06996119RecruitingPhase 1
Preventing graft-versus-host disease after stem cell transplant
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
Duarte, CaliforniaAges 18–75 - NCT01804634RecruitingPhase 2
Reduced-intensity stem cell transplant for high-risk solid tumors
This trial tests a less intense type of bone marrow (stem cell) transplant from a partly matched family donor for people with high-risk solid tumors. It aims to lower treatment intensity while still using the donor’s immune system to help control the cancer.
Baltimore, MarylandAges 1–50 - NCT01962415RecruitingPhase 2
Reduced-intensity stem cell transplant for non-cancer disorders
This trial tests whether a gentler (reduced-intensity) conditioning treatment before a stem cell transplant works for non-cancer diseases. It uses specific donor stem cell matches and checks heart, lung, liver, and kidney function to help lower transplant stress while still aiming for benefit.
Pittsburgh, PennsylvaniaAges 2 months–55 years - NCT00692939RecruitingPhase 1/Phase 2
Stem cell transplant for people with Crohn’s who need new options
This trial studies whether an “autologous” stem cell transplant (using your own cells) can improve Crohn’s disease that has not responded to standard treatments. It may help people who have ongoing, hard-to-control Crohn’s even after medicines and/or who have complications that make surgery risky.
Pittsburgh, PennsylvaniaAges 10–60 - NCT01704716RecruitingPhase 3
Study for high-risk neuroblastoma in children and teens
This Phase 3 trial tests treatments for children and teens with high-risk neuroblastoma, aiming to improve outcomes by using biology-based risk information. It also requires limited prior chemotherapy and specific timing after diagnosis.
AdelaideAges 1 month–21 years - NCT02605421RecruitingPhase 2
High-risk neuroblastoma stem cell treatment after initial response
This Phase 2 study tests intensive treatment (high-dose “consolidation”) followed by rescue with your own stem cells for high-risk neuroblastoma. It may help patients keep the cancer from coming back after it has improved or stabilized from initial chemotherapy.
Minneapolis, MinnesotaAges Up to 30 years - NCT02727803RecruitingPhase 2
Personalized natural killer cell therapy for blood cancers
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Houston, TexasAges 15–80 - NCT03125642RecruitingPhase 2
Auto stem cell transplant for lymphoma after chemo
This Phase 2 study tests an auto (self) stem cell transplant for people with certain types of non-Hodgkin lymphoma or Hodgkin lymphoma who respond to chemotherapy (they are “chemo-sensitive”). It may help some patients get a deeper or longer remission by resetting the bone marrow after high-dose treatment.
Minneapolis, MinnesotaAges Up to 75 years - NCT07559799Recruiting
Melflufen and Dexamethasone for Relapsed Multiple Myeloma
This study tracks how melflufen (a cancer-fighting drug) combined with dexamethasone works in patients with multiple myeloma that has returned or stopped responding to previous treatments. Researchers will monitor your health and quality of life over time to understand the treatment's real-world effectiveness.
Freiburg im BreisgauAges 18 years+ - NCT07588360Recruiting
Stem cell transplant for acute myeloid leukemia or myelodysplastic syndrome
This trial tests a type of stem cell transplant (using cells from a partially matched donor and umbilical cord blood) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to help patients whose disease is high-risk, has returned after treatment, or hasn't responded well to chemotherapy.
Fuzhou, FujianAges 14–60 - NCT05674539Enrolling by invitationPhase 3
Less intense transplant regimen for AML or MDS patients
This trial tests whether a less intense chemotherapy and transplant plan can work for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are getting a stem cell transplant. It may help reduce transplant-related harm, especially in people considered higher risk due to age or other health factors.
Wuhan, HubeiAges 18 years+
Common questions
- Are there clinical trials studying Melphalan?
- Yes. Clin2 currently lists 64 recruiting studies that include Melphalan, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Melphalan trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Melphalan an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Melphalan or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.